Sapient launches advanced FFPE Proteomics platform
The next-generation proteomics platform is designed to extract deep protein-level insights from archived tissue, enabling broad, integrated multi-omic mapping of tumor biology.
Sapient (CA, USA) this week announced the release of their MS-driven FFPE (formalin-fixed, paraffin-embedded) Proteomics platform that quantifies more than 10,000 proteins from a single 5-micron FFPE slide. Designed to overcome long-standing challenges in analyzing FFPE, the system offers unmatched depth across tumor and tissue samples, capturing phosphoproteins, glyco-proteins and rare protein variants with strong reproducibility.
FFPE samples represent one of the world’s most abundant biomedical resources, yet traditional technologies struggle to extract meaningful protein-level insights from them due to the impact of fixation on protein structures. Sapient’s new workflow captures more than 10,000 protein groups per 5 µm FFPE slide and provides insight into pathway activation, post-translational modifications and drug distribution, which are usually missed by traditional approaches such as DNA sequencing, RNA sequencing and immunohistochemistry.
You may also be interested in:
- 1M PMI: The launch event of the most ambitious study of human health in history?
- Scaling biomarker discovery: more data, deeper insights with Sapient Bioanalytics
- 2023 White Paper on recent issues in bioanalysis
Integrated with Sapient’s broader omics portfolio, including single-cell sequencing and spatial profiling, the platform supports comprehensive multi-omic mapping from genetic mutation to functional impact, with the ability to scale analyses across thousands of samples.
“What’s most exciting is that we can now go back to the vast biorepositories of FFPE tissue samples already collected, and using our method, essentially turn them into new discovery engines – unlocking previously hidden protein-level insights that add the critical layer of functional biology to existing genomics datasets,” explained Mo Jain, Founder and Chief Scientific Officer at Sapient.
“We can then go even further using our FFPE Multi-Omics platform, not only combining FFPE proteomics and DNA-seq but also single-cell sequencing and spatial profiling data to map tumor biology from mutation to pathway activation, cell-type and spatial localization.”
As part of the FFPE Proteomics platform, Sapient’s DynamIQTM virtual biobank further offers rapid access to thousands of annotated FFPE tumors and tissues for biopharma partners.
“By providing access to actionable FFPE tissue samples, we can support rapid retrospective studies to identify disease biomarkers, patient responders and drug mechanism of action insights that can optimize prospective studies and de-risk drug development efforts,” noted Jonathan Usuka, Chief Executive Officer at Sapient.
“We truly believe our complete FFPE offering will be a game-changer for discovery, translational and clinical teams in oncology and beyond.”
